Immuneering (NASDAQ:IMRX) Issues Earnings Results

Immuneering (NASDAQ:IMRX) announced its quarterly earnings data on Friday. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.09, FiscalAI reports.

Immuneering Price Performance

Immuneering stock traded up $0.02 during trading hours on Friday, hitting $5.16. The stock had a trading volume of 639,949 shares, compared to its average volume of 740,372. The stock’s fifty day moving average is $5.35 and its two-hundred day moving average is $5.70. Immuneering has a 1-year low of $1.29 and a 1-year high of $10.08. The stock has a market capitalization of $333.85 million, a price-to-earnings ratio of -4.41 and a beta of 0.37.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new position in shares of Immuneering during the 1st quarter worth $32,000. Geode Capital Management LLC lifted its position in Immuneering by 2.0% during the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after buying an additional 4,458 shares during the period. XTX Topco Ltd acquired a new stake in Immuneering in the 2nd quarter worth about $90,000. Bridgeway Capital Management LLC grew its holdings in Immuneering by 57.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock valued at $322,000 after buying an additional 35,000 shares during the period. Finally, Corient Private Wealth LLC purchased a new stake in Immuneering in the 2nd quarter valued at about $215,000. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on IMRX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a report on Friday, March 27th. Wall Street Zen raised Immuneering from a “sell” rating to a “hold” rating in a research report on Sunday, April 19th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Immuneering in a report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immuneering has an average rating of “Moderate Buy” and an average price target of $16.50.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.